Skip to main content
. 2022 Aug 27;27(1):23–33. doi: 10.1007/s10151-022-02661-6

Table 2.

Recurrences of pT1 rectal cancer patients after TEM/TAMIS (n = 36)

n (%)
Tumour risk
 Low-risk 24 (66.7)
 High-risk 9 (25.0)
 Missing 3 (8.3)
Location recurrence
 Local 34 (94.4)
 Distant 11 (30.6)
 Local and distant 9 (25.0)
Median time to local recurrence in months 11.1 (2.3–82.6)
Median time from TEM/TAMIS to salvage surgery in months 12.5 (4.4–58.4)
Location of local recurrence (pre-operative assessment)
 Intraluminal 29 (85.3)
 Nodal recurrence 5 (14.7)
Treatment of local recurrence
 No surgery 7 (20.6)
 Salvage surgery 27 (79.4)
  APR 13 (48.1)
  LAR 14 (51.9)
Radiotherapy
 None/not applicable 9 (26.5)
 Short-course radiotherapy 13 (38.2)
 Chemoradiation 11 (32.4)
 Long course radiotherapy 1 (2.9)
Pathological T-stage local recurrence
 pT0 2 (7.4)
 pT1 5 (18.5)
 pT2 2 (7.4)
 pT3 12 (44.4)
 pT4 2 (7.4)
 Missing 4 (14.8)
Pathological N-stage local recurrence
 pN0 12 (44.4)
 pN1 9 (33.3)
 pN2 2 (7.4)
 Missing 4 (14.8)
Local recurrence diagnosed based on
 MRI, endoscopy, ERUS 14 (41.2)
 MRI, endoscopy 5 (14.7)
 MRI, ERUS 1 (2.9)
 Endoscopy, ERUS 1 (2.9)
 MRI 7 (20.6)
 Endoscopy 5 (14.7)
 Missing 1 (2.9)

TEM transanal endoscopic microsurgery, TAMIS transanal minimally invasive surgery, APR abdominal perineal resection, LAR low anterior resection, MRI magnetic resonance imaging, ERUS endorectal ultrasound